Angiotech Announces Changes to Management and Board of Directors

VANCOUVER, Oct. 11, 2013 /CNW/ - Angiotech Pharmaceuticals, Inc. ("Angiotech") 
announced today that its shareholders and Board of Directors have approved 
changes to the Company's executive management team and Board of Directors. 
Effective October 8, Thomas Bailey and Angiotech mutually agreed that Mr. 
Bailey would transition from his current role as President and CEO of 
Angiotech, and into a Board role. As of that same date, at the Company's 
Annual General Meeting, Mr. Bailey was elected by the Company's shareholders 
to serve on Angiotech's Board of Directors. In addition, Kurt Cellar, Jeffrey 
Goldberg, Don Casey, Bradley Karro and Omar Vaishnavi were also re-elected to 
the Board of Directors. 
Mr. Victor Diaz, who has been named President and Chief Operating Officer, and 
Ms. Tammy Neske, Chief Business Officer, will report to the Board of 
Directors, and their respective roles and responsibilities will remain 
generally unchanged. Mr. Jay Dent will continue to serve as Senior Vice 
President and Chief Financial Officer. 
"We would like to offer thanks, on behalf of the Board and our shareholders, 
to Tom for his dedication and his many significant contributions during his 10 
years with Angiotech," said Kurt Cellar and Jeffrey Goldberg, Co-Chairs of 
Angiotech's Board of Directors. "Tom's determination and experience were 
critical in enabling the Company to navigate many challenges, and the hard 
work and operating acumen of Tom and his team set the stage for Angiotech's 
successful return to growth and profitability during the past two years. We 
look forward to continuing our work together as active members of the Board of 
"I would like to offer my sincere personal thanks to our shareholders, our 
Board, and most importantly to our dedicated executive team and employees, who 
have offered me the great privilege of working with them, and who have stood 
with me through both challenges and successes," said Mr. Bailey. "Our recent 
results, and the returns we've delivered to shareholders, have been due to a 
unique and highly cohesive team effort among our Board, management and 
employees, and I very much look forward to contributing to Angiotech's 
continued success as a member of our Board of Directors." 
Subsequent to the divestiture of its Interventional Products Business to Argon 
Medical this past spring, Angiotech changed the name of its operating business 
to Surgical Specialties Corporation. Surgical Specialties Corporation 
develops, manufactures and markets specialized surgical instruments, for its 
own brands as well as for selected private label and OEM customers. Surgical 
Specialties offers one of the most comprehensive portfolios of surgical 
blades, needles and sutures available for the specialty surgery market, and 
has trusted customer relationships and partnerships in the dental, ophthalmic, 
plastic surgery, dermatology, orthopedics, urology, microsurgery and trauma 
Forward Looking Statements 
Statements contained in this press release that are not based on historical 
fact, including without limitation statements containing the words "believes," 
"may," "plans," "will," "estimates," "continues," "anticipates," "intends," 
"expects" and similar expressions, constitute "forward-looking statements" 
within the meaning of the Private Securities Litigation Reform Act of 1995 and 
constitute "forward-looking information" within the meaning of applicable U.S. 
and Canadian securities laws. All such statements are made pursuant to the 
"safe harbor" provisions of applicable securities legislation. Forward-looking 
statements may involve, but are not limited to, comments with respect to our 
objectives and priorities in 2013 and beyond, our strategies or future 
actions, our targets, expectations for our financial condition and the results 
of, or outlook for, our operations, research and development and product 
development. Such forward-looking statements involve known and unknown risks, 
uncertainties and other factors that may cause the actual results, events or 
developments to be materially different from any future results, events or 
developments expressed or implied by such forward-looking statements. Many 
such known risks, uncertainties and other factors are taken into account as 
part of our assumptions underlying these forward-looking statements and 
include, among others, the following: general economic and business conditions 
in the United States, Canada and the other regions in which we operate; market 
demand; competition; technological changes that could impact our existing 
products or our ability to develop and commercialize future products; 
governmental legislation and regulations and changes in, or the failure to 
comply with, governmental legislation and regulations; availability of 
financial reimbursement coverage from governmental and third-party payers for 
products and related treatments; adverse results or unexpected delays in 
pre-clinical and clinical product development processes; adverse findings 
related to the safety and/or efficacy of our products or products sold by our 
partners; decisions, and the timing of decisions, made by health regulatory 
agencies regarding approval of our technology and products; the requirement 
for funding to conduct research and development, to expand manufacturing and 
commercialization activities; and any other factors that may affect our 
performance. In addition, our business is subject to certain operating risks 
that may cause any results expressed or implied by the forward-looking 
statements in this press release to differ materially from our actual results. 
These operating risks include: our ability to successfully manufacture, market 
and sell our products; changes in our business strategy or development plans; 
our ability to attract and retain qualified personnel; our ability to 
successfully complete pre-clinical and clinical development of our products; 
our failure to obtain patent protection for discoveries; loss of patent 
protection resulting from third-party challenges to our patents; 
commercialization limitations imposed by patents owned or controlled by third 
parties; our ability to obtain rights to technology from licensors; liability 
for patent claims and other claims asserted against us; our ability to obtain 
and enforce timely patent and other intellectual property protection for our 
technology and products; the ability to enter into, and to maintain, corporate 
alliances relating to the development and commercialization of our technology 
and products; market acceptance of our technology and products; the 
availability of capital to finance our activities; our ability to service our 
debt obligations; or any other factors. Given these uncertainties, assumptions 
and risk factors, investors are cautioned not to place undue reliance on such 
forward-looking statements. Except as required by law, we disclaim any 
obligation to update any such factors or to publicly announce the result of 
any revisions to any of the forward-looking statements contained in this press 
release to reflect future results, events or developments. 
©2013 Angiotech Pharmaceuticals, Inc. All Rights Reserved.

SOURCE  Angiotech Pharmaceuticals, Inc. 
Investor Relations and Corporate Communications Angiotech Pharmaceuticals, 
Inc. (604) 
To view this news release in HTML formatting, please use the following URL: 
CO: Angiotech Pharmaceuticals, Inc.
ST: British Columbia
-0- Oct/11/2013 13:00 GMT
Press spacebar to pause and continue. Press esc to stop.